Home > News > Centre to partly fund the cost of advanced R&D by biotech firms
December 31st, 2007
Centre to partly fund the cost of advanced R&D by biotech firms
Abstract:
The SCPP idea has been approved in principle, but would be placed before the government for formalization within a month. Meanwhile, DBT has sought industry proposals until March. Unlike the Small Business Innovation Research Initiative, or Sbiri, which is meant for small-and medium enterprises, SCPP is open to companies of all sizes.
"This would enable the industry to invest in areas like RNA interference, or RNAi, (a naturally occurring process that suppresses certain gene activity in cells and has evolved into a therapeutic technique to modulate the activity of single genes), nanotechnology-based fluidics, stem cells, et al., where the industry is currently not investing," said S. Natesh, a senior adviser at DBT in New Delhi. It would also include technologies for orphan crops, such as drought-resistant wheat and rice, those that can deal with environmental calamities, drugs and vaccines for national emergencies, and in such areas where initial commercialization looks unattractive for the industry.
Source:
livemint.com
Bookmark:
| Related News Press |
News and information
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Govt.-Legislation/Regulation/Funding/Policy
Metasurfaces smooth light to boost magnetic sensing precision January 30th, 2026
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||